Therapeutic antibodies against epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) combined with chemotherapy, as an important treatment for metastatic or recurrent CRC, have been widely used in clinic in recent years, but they have not significantly increased the 5-year survival rate of patients with advanced CRC [6]. Here, EGFR is linked to colorectal carcinoma.